公开(公告)号：EP4408433A1

公开(公告)日：2024-08-07

申请号：EP22877591.2

申请日：2022-09-29

申请人： Ionis Pharmaceuticals, Inc. ,  Bicycle TX Limited

发明人： SETH, Punit, P. ,  OESTERGAARD, Michael ,  CARRER, Michele ,  TANOWITZ, Michael ,  RIGBY, Michael ,  SKYNNER, Michael ,  STANWAY, Steven ,  URBONAS, Liudvikas ,  VAN RIETSCHOTEN, Katerine

IPC分类号： A61K31/70 ,  A61K31/7088 ,  A61K31/713 ,  A61K47/50 ,  A61K47/51 ,  A61K47/68 ,  A61K31/00 ,  A61K47/00

CPC分类号： C12N15/113 ,  A61K47/64 ,  A61K47/60 ,  C12Y207/11 ,  C12N15/1137 ,  C12N15/111 ,  C12N2310/1120130101 ,  C12N2310/351320130101 ,  C12N2320/3220130101 ,  C12N2310/334120130101 ,  C12N2310/31520130101 ,  C12N2310/323120130101 ,  C12N2310/1420130101 ,  C12Y204/02008 ,  C12N2310/351520130101 ,  A61K31/7088

公开(公告)号：EP4291652A1

公开(公告)日：2023-12-20

申请号：EP22753422.9

申请日：2022-02-11

申请人： Ionis Pharmaceuticals, Inc.

发明人： PRAKASH, Thazha, P. ,  OESTERGAARD, Michael ,  NIKAN, Mehran ,  FREESTONE, Graeme, C. ,  MIGAWA, Michael, T. ,  ANDERSON, Brooke, A. ,  SETH, Punit, P. ,  SWAYZE, Eric, E.

IPC分类号： C12N15/11 ,  A61K48/00

公开(公告)号：EP4013767A1

公开(公告)日：2022-06-22

申请号：EP20853270.5

申请日：2020-08-14

申请人： Ionis Pharmaceuticals, Inc.

发明人： LIANG, Xue-hai ,  SETH, Punit, P. ,  ANDERSON, Brooke, A. ,  DRURY III, William, John ,  OESTERGAARD, Michael ,  MIGAWA, Michael, T.

IPC分类号： C07H19/06 ,  A61K31/7088 ,  C12N15/113

公开(公告)号：EP3353305A1

公开(公告)日：2018-08-01

申请号：EP16849891.3

申请日：2016-09-26

申请人： Ionis Pharmaceuticals, Inc.

发明人： PRAKASH, Thazha, P. ,  LEE, Richard ,  SETH, Punit, P. ,  SWAYZE, Eric, E. ,  RIGO, Frank ,  OESTERGAARD, Michael

IPC分类号： C12N15/113

CPC分类号： C12N15/113 ,  C12N2310/11 ,  C12N2310/3231 ,  C12N2310/3341 ,  C12N2310/341 ,  C12N2310/346 ,  C12N2310/3515 ,  C12N2310/3517 ,  C12N2310/321 ,  C12N2310/3525

摘要： Provided herein are oligomeric compounds comprising a modified oligonucleotide and a conjugate group for modulating the amount or activity of a target nucleic acid in extra hepatic tissues and extra hepatic cells. Also provided herein are methods of modulating the amount or activity of an extra-hepatic nucleic acid target in a cell comprising contacting the cell with the oligomeric compound or antisense compound.

公开(公告)号：EP4257691A2

公开(公告)日：2023-10-11

申请号：EP23181919.4

申请日：2018-12-14

申请人： Ionis Pharmaceuticals, Inc.

发明人： OESTERGAARD, Michael ,  SETH, Punit P. ,  RIGO, Frank ,  DWYER, Chrissa A.

IPC分类号： C12N15/63

摘要： The present disclosure provides half duplex compounds comprising a first oligomeric compound and a second, shorter, oligomeric compound, wherein the first oligomeric compound is complementary to a target nucleic acid and the second oligomeric compound is complementary to the first oligomeric compound. In certain emobodiments, the compounds disclosed herein are useful for modulating the expression of extra-hepatic target nucleic acids.

公开(公告)号：EP3922722A1

公开(公告)日：2021-12-15

申请号：EP21161967.1

申请日：2012-08-08

申请人： Ionis Pharmaceuticals, Inc.

发明人： SETH, Punit P. ,  OESTERGAARD, Michael ,  SWAYZE, Eric E

IPC分类号： C12N15/113 ,  C12N15/11

摘要： The present invention provides oligomeric compounds. Certain such oligomeric compounds are useful for hybridizing to a complementary nucleic acid, including but not limited, to nucleic acids in a cell. In certain embodiments, hybridization results in modulation of the amount activity or expression of the target nucleic acid in a cell.

公开(公告)号：EP2951304B1

公开(公告)日：2020-07-08

申请号：EP14746305.3

申请日：2014-02-04

申请人： Ionis Pharmaceuticals, Inc.

发明人： OESTERGAARD, Michael ,  SETH, Punit, P. ,  SWAYZE, Eric, E.

IPC分类号： C07H21/02 ,  C07H1/00

公开(公告)号：EP3647318A1

公开(公告)日：2020-05-06

申请号：EP19191250.0

申请日：2015-04-28

申请人： Ionis Pharmaceuticals, Inc.

发明人： WAN, W. Brad ,  MIGAWA, Michael T. ,  OESTERGAARD, Michael ,  SWAYZE, Eric E. ,  SETH, Punit P.

IPC分类号： C07H19/067 ,  C07H19/167 ,  C07H21/02 ,  C12N15/11

摘要： The present invention provides oligomeric compounds comprising at least one neutral methoxypropyl phosphonate modified internucleoside linkage. Such oligomeric compounds have one or more improved properties such as selectivity, potency, improved toxicity profile and or improved proinflammatory profile. Such oligomeric compounds have enhanced stability to exposure to base during synthesis. Certain such oligomeric compounds are useful for hybridizing to a complementary nucleic acid, including but not limited, to nucleic acids in a cell. In certain embodiments, hybridization results in modulation of the amount activity or expression of the target nucleic acid in a cell.

公开(公告)号：EP3194591A1

公开(公告)日：2017-07-26

申请号：EP15842185.9

申请日：2015-09-21

申请人： Ionis Pharmaceuticals, Inc.

发明人： OESTERGAARD, Michael ,  SETH, Punit, P.

IPC分类号： C12N15/00 ,  C12N15/113

CPC分类号： C12N15/113 ,  A61K51/0491 ,  C07F9/595 ,  C07H21/00 ,  C12N15/111 ,  C12N2310/11 ,  C12N2310/113 ,  C12N2310/315 ,  C12N2310/32 ,  C12N2310/3231 ,  C12N2310/33 ,  C12N2310/3341 ,  C12N2310/341 ,  C12N2310/351 ,  C12N2310/3517 ,  C12N2320/51 ,  C12N2310/322 ,  C12N2310/3525

摘要： The present disclosure provides oligomeric compounds. The present disclosure provides metabolically stable linkers that do not rapidly degrade in vivo. In certain embodiments, the present disclosure provides metabolically stable linkers for use in attaching a conjugate group to an oligonucleotide.

摘要翻译： 本公开提供了寡聚化合物。 本公开提供了不会在体内迅速降解的代谢稳定的连接体。 在某些实施方案中，本公开内容提供了用于将缀合物基团连接至寡核苷酸的代谢上稳定的接头。

公开(公告)号：EP2742056B1

公开(公告)日：2017-01-11

申请号：EP12822510.9

申请日：2012-08-08

申请人： Ionis Pharmaceuticals, Inc.

发明人： SETH, Punit, P. ,  OESTERGAARD, Michael ,  SWAYZE, Eric, E.

IPC分类号： C12N15/113 ,  C12N15/11 ,  A61K31/7088

CPC分类号： C12N15/113 ,  C12N15/111 ,  C12N2310/11 ,  C12N2310/312 ,  C12N2310/3125 ,  C12N2310/315 ,  C12N2310/316 ,  C12N2310/321 ,  C12N2310/3231 ,  C12N2310/3341 ,  C12N2310/341 ,  C12N2310/351 ,  C12N2320/34 ,  C12N2310/3525